Aladar Szalay Sells 33,061 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 33,061 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $3.30, for a total transaction of $109,101.30. Following the sale, the insider now owns 1,195,731 shares in the company, valued at $3,945,912.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 29th, Aladar Szalay sold 6,403 shares of Genelux stock. The stock was sold at an average price of $3.25, for a total transaction of $20,809.75.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Up 6.1 %

Shares of GNLX opened at $3.48 on Friday. The stock has a 50 day moving average price of $5.41 and a 200 day moving average price of $10.31. Genelux Co. has a 52-week low of $3.06 and a 52-week high of $40.98.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Research analysts anticipate that Genelux Co. will post -0.81 EPS for the current year.

Analysts Set New Price Targets

GNLX has been the topic of a number of recent research reports. Benchmark restated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright cut their target price on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodward Diversified Capital LLC boosted its holdings in Genelux by 0.3% in the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares in the last quarter. LifeSteps Financial Inc. boosted its holdings in Genelux by 26.6% in the first quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company’s stock valued at $285,000 after purchasing an additional 9,301 shares in the last quarter. Clarity Capital Partners LLC acquired a new stake in shares of Genelux in the fourth quarter valued at approximately $364,000. Tower Research Capital LLC TRC boosted its holdings in shares of Genelux by 216.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after acquiring an additional 2,021 shares during the period. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Genelux in the fourth quarter valued at approximately $196,000. 37.33% of the stock is owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.